摘要
Dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, and low high-densitylipoprotein （HDL） cholesterinemia, is a key risk factor to atherosclerosis. The detrimental effect of elevated low-density lipoprotein （LDL） cholesterol and/or decreased HDL cholesterol on cardiovascular disease risk had been well established from previous studies.1 Recently, emerging evidences suggest that dyslipidemia may also be an important contributor to morbidity and mortality of chronic kidney disease （CKD）, which has received more and more attention as the prevalence of CKD increases.
Dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, and low high-densitylipoprotein （HDL） cholesterinemia, is a key risk factor to atherosclerosis. The detrimental effect of elevated low-density lipoprotein （LDL） cholesterol and/or decreased HDL cholesterol on cardiovascular disease risk had been well established from previous studies.1 Recently, emerging evidences suggest that dyslipidemia may also be an important contributor to morbidity and mortality of chronic kidney disease （CKD）, which has received more and more attention as the prevalence of CKD increases.
